ClinicalTrials.gg
Active, not recruitingNCT02109952Updated Oct 16, 2026

Biomechanics of Metastatic Defects in Bone

An observational study in Cancer Bone and Bone Tumors, sponsored by Beth Israel Deaconess Medical Center. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Beth Israel Deaconess Medical Center · Observational

How we know

Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
245
Ages
20 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Bone Neoplasms with a site in United States — 23 open to participants now, 36 under way, 1 of them phase 3. Bone Neoplasms · United States.

Planned enrollment
7th of 26
245 · median 87
Started
2009
with 3 others
Observational
27 of 113
9 open now
Primary completion
2027-12
later than 23 of 35 live
Registered
46th of 113
by date

Among the 113 studies in Bone Neoplasms with a site in United States, this one is the 7th largest by planned enrollment of the 26 observational ones that give a count, is one of 4 that started in 2009, is one of 27 observational ones, reaches primary completion later than 23 of the 35 other live ones, and was the 46th registered.

Bone Neoplasms

259 studies on the registry are indexed under Bone Neoplasms; 70 are open to participants now.

Browse Bone Neoplasms studies →

Open to participants now

23 of the 113 studies in Bone Neoplasms with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Bone Neoplasms studies recruiting now, 35 (65%) set no upper age limit and 13 (24%) stop at 75 or younger; 25 take children under 18; 4 take healthy volunteers.

This study: 20 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Bone Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to monitor fracture risk associated with bone tumors in cancer patients.

Previous studies from our lab have suggested that it is possible to compute the mechanical strength of bones with tumors using computed tomography (CT) scans, which are like three-dimensional X-ray pictures of the affected bones.

The next step in determining the usefulness of this type of strength analysis is to see if we can accurately predict who is at risk for bone fracture and which patients are at high risk of fractures.

This non-invasive analysis may help physicians determine the best treatment to reduce the risk of an impending bone fracture in the future.

Read the detailed description

If a patient agrees to participate in this study, we will ask the patient to complete two written, self-administered questionnaires. The questionnaires will take about fifteen minutes to complete and contain questions about the patient's general health as well as questions specific to the site of the bone tumor. The patient will be asked to complete the first questionnaire upon enrollment in the study, and the second when participation in the study is concluded. The patient will be asked to complete and return the questionnaire to the project coordinator at this time. If for any reason the patient is unable to complete the questionnaire at this time, he/she will be asked to return it to the project coordinator within two weeks using a stamped, pre-addressed envelope, which will be provided.

The treating physician has ordered both an X-ray picture and a three-dimensional CT scan image of the involved bone plus the contralateral limb (lower limbs). He/she will be provided with a standard report from the radiologist describing the appearance of the bone tumor and the bone itself which the treating physician will use to determine the course of treatment he/she deems appropriate. We will perform a special analysis of the CT images that will allow us to estimate the strength of the bone with the tumor. Based on this engineering analysis of the strength of the bone, the treating physician may alter the prescribed treatment to decrease the risk that bone will fracture. If the patient does not have a fracture within the follow-up period (four months), he/she will undergo a second CT scan to determine the response of the tumor to treatment and changes in the strength of the bone. If the patient does have a fracture within the follow-up period, he/she will undergo a second CT scan to determine the integrity of the remaining bone to help your physician plan the next course of action. We will use the second CT scan to estimate how weak the bone was just prior to fracture. In either case, the patient's participation in this study will be concluded after the second CT scan.

Patient participation in the study will last four months. If the patient has a fracture before four months, his/her participation will end at that time.

The investigator and/or the treating physician may decide to take the patient off this study if

  1. patient refuses or is unable to complete study procedures;
  2. patient develops weakness or numbness in his/her limbs due to your disease;
  3. patient's bone fractures due to significant trauma (e.g., traffic accident, fall from height);
  4. a different bone fractures, limiting patient's ability to put pressure on the bone of interest; or
  5. patient relocate.

The patient can end his/her participation at any time. The patient's decision to withdraw from the study will not affect in any way his/her medical care and/or benefits. If the patient decides to end his/her participation in the study, we encourage him/her to discuss the decision the treating physician.

STUDY LOCATION Privacy Patients will be approached by treating physicians at clinic and privately (in the examination room), where they can privately describe the study, answer any questions the patient might have and potentially enroll the patient in the study. Patient privacy and confidentiality will be strictly observed during all steps of recruitment, reporting of data and follow up conversations.

Physical Setting

All patient related activity will be conducted in the hospital as the patient undergoes treatment. CT data analysis will be performed at the Center for advanced Orthopaedic Studies at BIDMC.

DATA SECURITY All data will be kept behind BIDMC firewall at an access controlled computer designated for this study only. Additionally, the patient data will be anonymized and a number will be assigned to protect the patient identity, therefore those conducting analysis on the CT data will have no access to patient identifiable information.

03

Conditions studied

  • Cancer Bone
  • Bone Tumors

Browse trials for

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

When a patient presents to the orthopaedic oncologist with lower appendicular skeletal skeletal metastasis, as per standard clinical practice biplanar radiographs and CT scans of the involved bone(s) plus the contralateral limb will be obtained. Informed consent will be obtained for CT scan with the contralateral limb (Both limbs are in the gantry and are imaged together-this is not an additional step, as this is how patients are scanned for general care of lesions in the lower limbs) to provide a patient specific internal control and calcium hydroxyapatite phantom for standardizing bone density estimates. Post-processing of the image data will be conducted by the Orthopaedic Biomechanics Lab at BIDMC to calculate fracture risk associated with the bone lesion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient with cancer bone lesions

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
245 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Fracture Risk Assessment in Patients with Skeletal Metastasis

    Based on past studies, metastatic lesion in cancer bone alters both the material and geometric properties of the bone while rigidity, the structural property, integrates both two properties in bone. For a cancerous bone, the axial (EA), bending (EI), and torsional (GJ) rigidity determine the capacity of the bone to resist axial, bending and twisting loads respectively. Because the weakest segment of the bone dictates the load capacity of the entire bone, we have developed algorithms to calculate the minimal rigidity of a bone with an osteolytic lesion using serial, trans-axial, computed tomography (CT) images through the affected bone to measure both the bone tissue mineral density and cross-sectional geometry. If the ratio of EA, EI or GI in compare with the normal bone's EA, EI, or GI was 65% or less, pathological fracture will be predicted. This non-invasive analysis may help physicians determine the best treatment to reduce the risk of an impending bone fracture in the future.

    Time frame: 0-4 Months

Secondary outcomes

  1. Fracture Risk Assessment in Patients with Skeletal Metastasis (Following-up with Changes)

    Time frame: 4-12 Months

07

Study locations

8 sites
  • Alvin and Lois Lapidus Cancer Center, Sinai Hospital of Baltimore, Inc
    Baltimore, Maryland 21215, United States
  • Department of Orthopaedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School
    Boston, Massachusetts, United States
  • Department of Orthopaedic Surgery, University of Minnesota Medical Center
    Minneapolis, Minnesota, United States
  • Department of Orthopedic Surgery, Upstate Medical University
    Syracuse, New York 13057, United States
  • Department of Orthopaedic Surgery, Rhode Island Hospital
    Providence, Rhode Island 02905, United States
  • Section of Orthopaedic Oncology, University of Texas M. D. Anderson Cancer Center
    Houston, Texas, United States
  • Edwards Comprehensive Cancer Center, Marshall University
    Huntington, West Virginia, United States
  • Department of Orthopaedic Surgery, McGill University Health Centre
    Montreal, Quebec, Canada
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jan 2009, a primary completion of Dec 2027 and a completion of Dec 2027. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2014
First posted
Apr 10, 2014
Start
Jan 2009
Primary completionEst.
Dec 31, 2027was Dec 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2025→Dec 31, 2027
Oct 16, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Dec 31, 2025→Dec 31, 2027
    Study completion Dec 31, 2025→Dec 31, 2027
    + 3 other changes: verification date, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02109952
Responsible party
Ara Nazarian (Assistant Professor of Orthopedic Surgery, Beth Israel Deaconess Medical Center) — Principal investigator
First posted
Apr 10, 2014
Start date
Jan 2009
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Ara Nazarian, PhD
principal investigator · anazaria@bidmc.harvard.edu

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion